Bellevue Life Sciences Acquisition Corp. (BLAC) Stock
Bellevue Life Sciences Acquisition Corp. currently does not engage in substantial operational activities.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Bellevue Life Sciences Acquisition Corp.
Bellevue Life Sciences Acquisition Corp. currently does not engage in substantial operational activities. Its core mission is to orchestrate a business combination, which could manifest as a merger, share exchange, asset acquisition, stock purchase, recapitalization, or reorganization, with one or more enterprises or organizations within the healthcare domain. This firm, established in 2020, maintains its principal office in Bellevue, Washington, and operates as a subordinate entity of Bellevue Global Life Sciences Investors LLC.
Bellevue Life Sciences Acquisition Corp. is headquartered in US.
Bellevue Life Sciences Acquisition Corp. (BLAC) stock trades at $3.01 with a market capitalization of $6.98M. The stock is valued at a price-to-earnings (P/E) ratio of 1.23, price-to-book of 0.11, price-to-sales of 2.66. Over the past 52 weeks the stock has ranged between $3.01 and $13.40, and currently trades 77.5% below its 52-week high.
On profitability, Bellevue Life Sciences Acquisition Corp. generates a return on equity (ROE) of 7.91%, return on capital employed of -12.37%, an operating margin of -726.07%, a net profit margin of 301.52%.
Official website: www.bellevuespac.com
Bellevue Life Sciences Acquisition Corp. by the numbers, 2020–2025
Between 2020 and 2025 Bellevue Life Sciences Acquisition Corp. reported revenue of $0 rising to $3.0M. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-29.0M in 2025.
The most recent net margin is 301.52%. On a trailing twelve-month basis to Mar '26, revenue is $2.0M and net profit $9.0M.
Borrowings stand at $0, cash on hand is $1.6M, cash from operations was $0 in the latest year, positive in 0 of the last 6.
Return on equity has averaged 16.7% over five years, and was 33.3% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Bellevue Life Sciences Acquisition Corp. (BLAC) — frequently asked questions
What is Bellevue Life Sciences Acquisition Corp. (BLAC) stock price today?
Bellevue Life Sciences Acquisition Corp. (BLAC) is currently trading at $3.01, down 55.27% today.
What is BLAC P/E ratio?
Bellevue Life Sciences Acquisition Corp.'s P/E ratio is 1.23. This is below the typical market average of roughly 18-22x. A low P/E can reflect a lower valuation, slower expected growth, or both.
What is BLAC return on equity (ROE)?
Bellevue Life Sciences Acquisition Corp.'s return on equity (ROE) is 7.91%. ROE measures net income relative to shareholders' equity. This is below the typical market range of roughly 12-15%.
What is Bellevue Life Sciences Acquisition Corp.'s market cap?
Bellevue Life Sciences Acquisition Corp. has a market capitalization of $6.98M.
Does BLAC pay a dividend?
Bellevue Life Sciences Acquisition Corp. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does BLAC carry?
Bellevue Life Sciences Acquisition Corp. has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is BLAC's profit margin?
Bellevue Life Sciences Acquisition Corp. reports a net profit margin of 301.52% — the share of revenue left after every cost, including tax and interest.
What sector is BLAC in?
Bellevue Life Sciences Acquisition Corp. is classified under Financial Services, in the Shell Companies industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is BLAC listed on?
Bellevue Life Sciences Acquisition Corp. trades on NASDAQ under the ticker BLAC.
What is BLAC's 52-week range?
Over the last year Bellevue Life Sciences Acquisition Corp. has traded between $3.01 and $13.40.
Related Financial Services Stocks
Popular Stocks
Screens BLAC currently matches
On the figures above, Bellevue Life Sciences Acquisition Corp. passes the filters for 5 of our ready-made screens, among them Day Losers Stocks, Penny Stocks, Best Penny Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.